Risk of Hepatotoxicity in Patients With Gout Treated With Febuxostat or Benzbromarone: A Propensity Score–Matched Cohort Study
Main finding · HepatotoxicityResult — go to the resultAdjusted hazard ratio 2.75 95% CI 1.28–5.91Authors' conclusion
Febuxostat use is associated with a significantly greater risk of mild-to-moderate perturbation of liver function compared to benzbromarone in patients with gout.
Study context
- Population
- Patients with gout, new users of febuxostat or benzbromarone, from an electronic medical record databaseeligible
- Participants
- 2,338 patients
- Exposure
- Febuxostat vs benzbromarone
- Febuxostatn = 488
- Benzbromaronen = 488reference
- Outcome
- Hepatotoxicity (ALT or AST > 3× upper limit of normal)
Methodological detailspropensity score matched 1:1 for age, sex, pretreatment ALT and AST, electronic medical record database, new users, Cox regression
- Propensity score matched 1:1 for age, sex, pretreatment ALT and AST
- Electronic medical record database
- New users
- Cox regression
Main finding
Hepatotoxicity
Adjusted hazard ratio
2.75
95% CI 1.28–5.91
By group
Febuxostatvs Benzbromarone
aHR 2.75 (95% CI 1.28–5.91)
As reported in the abstract
Observational data: associations, not effects.
Further findings
Prespecified subgroups (age, BMI, comorbidities)
- Findings did not differ according to prespecified subgroups
CTCAE v5 grades 1 to 3 AST or ALT abnormality (all eligible patients)
- Proportion of patients
- 37%
Original publication
Risk of Hepatotoxicity in Patients With Gout Treated With Febuxostat or Benzbromarone: A Propensity Score–Matched Cohort Study. Arthritis Care Res (Hoboken). Published 8 May 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →